Latest Licensing Agreements News

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Linius Technologies has implemented a sweeping operational restructure, cutting expenses by more than 60% compared to FY25, while progressing a pivotal proof of concept with a major European football league and securing over $3.7 million in new funding.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Temas Resources has completed its acquisition of ORF Technologies, gaining full ownership of the patented Regenerative Chloride Leach (RCL) technology that promises significant cost and environmental advantages in critical metals processing.

Environmental Clean Technologies Limited is set to acquire exclusive rights to Rice University’s breakthrough Flash Joule Heating technology for PFAS soil remediation, backed by a $3 million capital raise and leadership changes.

Zeus Resources has completed its acquisition of the Casablanca Antimony Project in Morocco, revealing promising geophysical survey results and appointing a seasoned US strategic advisor to boost international partnerships.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

Algorae Pharmaceuticals has broadened its commercial footprint in Australia and New Zealand through key licensing agreements, while advancing its AI-driven drug discovery platform and strengthening leadership.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.